As emphasized by the Centers for Disease Control and Prevention (CDC), obesity is a complex, chronic condition
Its long-term safety profile, optimal dosing, and broader clinical utility remain under investigation in ongoing Phase 3 trials
The American Diabetes Association (ADA) Standards of Care recommend GLP-1 receptor agonists like semaglutide as preferred agents for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or indicators of high cardiovascular risk, based on demonstrated cardiovascular benefits in outcome trials
On April 1, 2026, the U.S
Hence its sale is illegal, and they are still unapproved for use
Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys